Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL6 | P05231 | 8/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581433 | 0.93 | IL6 (0.52) | IL6DRD3ALDH1A1DRD2DRD4 | |
| SCHEMBL4582028 | 0.91 | IL6 (0.53) | IL6ALDH1A1LMNAF2KMT2A | |
| SCHEMBL4139329 | 0.89 | IL6 (0.46) | IL6DRD3ALDH1A1ACHELMNA | |
| SCHEMBL4581986 | 0.88 | IL6 (0.49) | IL6ALDH1A1LMNAKMT2A | |
| SCHEMBL4582868 | 0.87 | IL6 (0.49) | IL6ALDH1A1LMNAKMT2A | |
| SCHEMBL4134561 | 0.87 | IL6 (0.48) | IL6DRD3ALDH1A1DRD2DRD4 | |
| SCHEMBL4581171 | 0.87 | IL6 (0.48) | IL6DRD3ALDH1A1DRD2DRD4 | |
| SCHEMBL4139189 | 0.87 | IL6 (0.47) | IL6DRD3ALDH1A1DRD2DRD4 | |
| SCHEMBL4143624 | 0.86 | IL6 (0.49) | IL6DRD3ALDH1A1DRD2DRD4 | |
| SCHEMBL452377 | 0.86 | IL6 (0.51) | IL6ALDH1A1LMNAF2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975256-B2 | 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-03-10 | — | — | US | disclosed |
| US-8551991-B2 | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8551991-B2 | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-1995242-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1995242-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111807-A1 | Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity | NR3C1, NR3C2, MC2R | IL6 3728/4885DRD3 291/4885ALDH1A1 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.